MedTrace Logo

Single Ascending Dose Study With Healthy Male Volunteers and Type II Diabetic Patients

NCT00886366 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2010-12-07

No results posted yet for this study

Summary

The purpose of this study is to assess safety and tolerability of AZD6714 after single ascending oral doses in healthy male subjects and type 2 diabetic patients.

Conditions

Interventions

DRUG

AZD6714

Oral single doses a-h suspension

DRUG

Placebo

Oral single doses suspension

DRUG

AZD6714

Oral single doses a-d suspension

DRUG

AZD6714

Oral single doses d and g suspension

Sponsors & Collaborators

Principal Investigators

  • Klas Malmberg, MD, PhD · AstraZeneca R&D Mölndal

  • Marianne Hartford · CPU Sahlgrenska University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2009-09-30
Completion
2009-09-30

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00886366 on ClinicalTrials.gov